Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$161.01 - $317.85 $31.9 Million - $63 Million
198,264 Added 5082.39%
202,165 $64 Million
Q3 2023

Nov 14, 2023

BUY
$164.66 - $218.08 $191,170 - $253,190
1,161 Added 42.37%
3,901 $659,000
Q2 2023

Aug 11, 2023

SELL
$176.32 - $240.22 $195,538 - $266,403
-1,109 Reduced 28.81%
2,740 $594,000
Q1 2023

May 15, 2023

SELL
$161.33 - $204.36 $115,996 - $146,934
-719 Reduced 15.74%
3,849 $699,000
Q4 2022

Feb 14, 2023

SELL
$191.53 - $236.82 $341,306 - $422,013
-1,782 Reduced 28.06%
4,568 $898,000
Q3 2022

Nov 14, 2022

BUY
$123.79 - $277.42 $398,232 - $892,460
3,217 Added 102.68%
6,350 $1.43 Million
Q2 2022

Aug 15, 2022

BUY
$93.97 - $143.33 $294,408 - $449,052
3,133 New
3,133 $396,000

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Magnetar Financial LLC Portfolio

Follow Magnetar Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Magnetar Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Magnetar Financial LLC with notifications on news.